Evaluation of the Effect of GSK-3β on Liver Cancer Based on the PI3K/AKT Pathway

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Aug 19

PMID 39156976

Authors

Jiageng Guo

Xinya Jiang

Jing Lian

Huaying Li

Fan Zhang

Jinling Xie

Jiagang Deng

Xiaotao Hou

Zhengcai Du

Erwei Hao

Affiliations

Soon will be listed here.

Abstract

The PI3K/AKT/GSK-3β signaling pathway plays a pivotal role in numerous physiological and pathological processes, including cell proliferation, apoptosis, differentiation, and metabolic regulation. Aberrant activation of the PI3K/AKT pathway is intricately linked to development of tumor. GSK-3β, belonging to the serine/threonine protein kinase family, is crucial in the pathogenesis of liver cancer. As a key rate-limiting enzyme in the glucose metabolism pathway, GSK-3β significantly impacts the growth, proliferation, metastasis, and apoptosis of liver cancer cells. It is also implicated in chemotherapy resistance. Elevated expression of GSK-3β diminishes the sensitivity of liver cancer cells to chemotherapeutic agents, thereby playing a substantial role in the development of drug resistance. Consequently, targeting of GSK-3β, particularly within the PI3K/AKT signaling pathway, is regarded as a promising therapeutic strategy for liver cancer. The precise identification and subsequent modulation of this pathway represent a substantial potential for innovative clinical interventions in the management of liver cancer.

Citing Articles

TRPM channels in human cancers: regulatory mechanism and therapeutic prospects.

Liu Q, Hu M, Li S, Zhang X, Zhang R, Lyu H Biomark Res. 2024; 12(1):152.

PMID: 39633507 PMC: 11616203. DOI: 10.1186/s40364-024-00699-2.

References

Jope R, Johnson G . The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004; 29(2):95-102. DOI: 10.1016/j.tibs.2003.12.004. View

Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X . Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2019; 30(6):571-579. PMC: 6328503. DOI: 10.21147/j.issn.1000-9604.2018.06.01. View

Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View

Li L, Chai Y, Guo X, Chu S, Zhang L . Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 2018; 17(6):7886-7892. DOI: 10.3892/mmr.2018.8840. View

Tournoux C, Paoletti X, Barbare J . Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2007; 33(8):762-3. DOI: 10.1016/j.ctrv.2007.06.001. View

Yang N, Zhou J, Li Q, Han F, Yu Z . miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. Cancer Cell Int. 2019; 19:38. PMC: 6381685. DOI: 10.1186/s12935-019-0756-7. View

Zheng W, Yao M, Qian Q, Sai W, Qiu L, Yang J . Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget. 2017; 8(32):52321-52332. PMC: 5581031. DOI: 10.18632/oncotarget.13674. View

Sharma A . Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017; 12(17):2137-2148. DOI: 10.2217/nnm-2017-0184. View

Thummar K, Rathinam C . Class I PI3K regulatory subunits control differentiation of dendritic cell subsets and regulate Flt3L mediated signal transduction. Sci Rep. 2022; 12(1):12311. PMC: 9296662. DOI: 10.1038/s41598-022-16548-x. View

10.

Richardson P, Eng C, Kolesar J, Hideshima T, Anderson K . Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5):623-33. PMC: 4467022. DOI: 10.1517/17425255.2012.681376. View

11.

Zhang C, Pan R, Ma S, Xu S, Wang B . Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer. Open Med (Wars). 2022; 17(1):2052-2061. PMC: 9755696. DOI: 10.1515/med-2022-0541. View

12.

Takahashi-Yanaga F . Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013; 86(2):191-9. DOI: 10.1016/j.bcp.2013.04.022. View

13.

Liu Y, Deguchi Y, Tian R, Wei D, Wu L, Chen W . Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019; 79(5):954-969. PMC: 6397663. DOI: 10.1158/0008-5472.CAN-18-1790. View

14.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

15.

Doble B, Woodgett J . GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003; 116(Pt 7):1175-86. PMC: 3006448. DOI: 10.1242/jcs.00384. View

16.

Bai C, Zhao J, Su J, Chen J, Cui X, Sun M . Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling. Life Sci. 2022; 306:120804. DOI: 10.1016/j.lfs.2022.120804. View

17.

Brooks Robey R, Hay N . Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol. 2009; 19(1):25-31. PMC: 2814453. DOI: 10.1016/j.semcancer.2008.11.010. View

18.

Huang E, Xue S, Zhang Z, Zhou J, Guan Y, Tang Y . Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis. 2012; 17(10):1120-30. DOI: 10.1007/s10495-012-0743-0. View

19.

Yudushkin I . Control of Akt activity and substrate phosphorylation in cells. IUBMB Life. 2020; 72(6):1115-1125. PMC: 7317883. DOI: 10.1002/iub.2264. View

20.

Martinez A, Perez D . GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. J Alzheimers Dis. 2008; 15(2):181-91. DOI: 10.3233/jad-2008-15204. View